Institutional investors purchased a net $2.0 million shares of GENE during the quarter ended December 2014. This may signal that the smart money is gaining interest in this company as the 17.84% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
HEIGHTS CAPITAL MANAGEMENT, INC. Bought 1.1 Million shares of Genetic Technologies Ltd